This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carette, J. E. Articles by van Beusechem, V. W. Search for Related Content PubMed PubMed Citation Articles by Carette, J. E. Articles by van Beusechem, V. W.

Conditionally Replicating Adenoviruses Expressing Short Hairpin RNAs Silence the Expression of a Target Gene in Cancer Cells

¹ Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands; ² Translational Research Laboratory, Institut Catala d’Oncologia, Barcelona, Spain; and ³ Harry B. and Aileen Gordon Diabetes Research Laboratory, Molecular Diabetes and Metabolism Section, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

RNA interference (RNAi) is a posttranscriptional silencing mechanism triggered by double-stranded RNA that was recently shown to function in mammalian cells. Expression of cancer-associated genes was knocked down by expressing short hairpin RNAs (shRNAs) in cancer cells. By virtue of its excellent target specificity, RNAi may be used as a new therapeutic modality for cancer. The success of this approach will largely depend on efficient delivery of shRNAs to tumor cells. Tumor-selective replication competent viruses are especially suited to efficiently deliver anticancer genes to tumors. In addition, their intrinsic capacity to kill cancer cells makes these viruses promising anticancer agents per se. In this study, conditionally replicating adenoviruses were constructed encoding shRNAs targeted against firefly luciferase. These replicating viruses were shown to specifically silence the expression of the target gene in human cancer cells down to 30% relative to control virus. This finding offers the promise of using RNAi in the context of cancer gene therapy with oncolytic viruses.

This article has been cited by other articles:

				Y. Dai, L. Qiao, K. W. Chan, M. Yang, J. Ye, R. Zhang, J. Ma, B. Zou, C. S.C. Lam, J. Wang, et al. Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer Mol. Cancer Ther., September 1, 2009; 8(9): 2762 - 2770. [Abstract] [Full Text] [PDF]

				R. Juliano, Md. R. Alam, V. Dixit, and H. Kang Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides Nucleic Acids Res., July 1, 2008; 36(12): 4158 - 4171. [Abstract] [Full Text] [PDF]

				Y.-A. Zhang, J. Nemunaitis, S. K. Samuel, P. Chen, Y. Shen, and A. W. Tong Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering RNA Cancer Res., October 1, 2006; 66(19): 9736 - 9743. [Abstract] [Full Text] [PDF]

				A. Godfrey, J. Anderson, A. Papanastasiou, Y. Takeuchi, and C. Boshoff Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA Blood, March 15, 2005; 105(6): 2510 - 2518. [Abstract] [Full Text] [PDF]